Total Payments
$3,343
2024 Payments
$317.87
Companies
23
Transactions
126
Medicare Patients
10,383
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$3,144 (94.1%)
Other$105.70 (3.2%)
Education$92.99 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,144 | 124 | 94.1% |
| Entertainment | $105.70 | 1 | 3.2% |
| Education | $92.99 | 1 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $469.57 | 38 | $0 (2021) |
| BIOTISSUE HOLDINGS INC. | $353.36 | 3 | $0 (2024) |
| ABBVIE INC. | $327.26 | 18 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $299.80 | 11 | $0 (2024) |
| Intersect ENT, Inc. | $278.90 | 3 | $0 (2018) |
| Alcon Vision LLC | $245.18 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $203.52 | 13 | $0 (2023) |
| THE CAMERON-EHLEN GROUP, INC. | $201.74 | 2 | $0 (2019) |
| Johnson & Johnson Surgical Vision, Inc. | $166.55 | 3 | $0 (2019) |
| Glaukos Corporation | $141.70 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $317.87 | 6 | Alcon Vision LLC ($120.48) |
| 2023 | $326.28 | 19 | ABBVIE INC. ($180.33) |
| 2022 | $512.56 | 18 | BioTissue Holdings, Inc. ($237.75) |
| 2021 | $396.47 | 24 | Allergan, Inc. ($201.36) |
| 2020 | $510.21 | 23 | Allergan, Inc. ($195.00) |
| 2019 | $285.32 | 15 | Allergan Inc. ($73.21) |
| 2018 | $418.47 | 11 | Intersect ENT, Inc. ($124.04) |
| 2017 | $575.36 | 10 | The Cameron-Ehlen Group, Inc. ($198.15) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Ophthalmology | ||||||
| 07/23/2024 | Alcon Vision LLC | NGENUITY (Device), Luxor | Food and Beverage | In-kind items and services | $120.48 | General |
| Category: Ophthalmology | ||||||
| 07/22/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $115.61 | General |
| 05/08/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: EYE CARE | ||||||
| 05/01/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/04/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/29/2023 | ABBVIE INC. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: EYE CARE | ||||||
| 11/01/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: TEPEZZA | ||||||
| 10/17/2023 | ABBVIE INC. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $5.69 | General |
| Category: EYE CARE | ||||||
| 10/05/2023 | ABBVIE INC. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: EYE CARE | ||||||
| 09/21/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: TEPEZZA | ||||||
| 08/17/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: TEPEZZA | ||||||
| 05/25/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Ophthalmology | ||||||
| 05/19/2023 | ABBVIE INC. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $4.59 | General |
| Category: EYE CARE | ||||||
| 04/26/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Ophthalmology | ||||||
| 04/12/2023 | ABBVIE INC. | ALPHAGAN P (Drug), LUMIGAN | Food and Beverage | In-kind items and services | $34.47 | General |
| Category: EYE CARE | ||||||
| 04/05/2023 | ABBVIE INC. | ALPHAGAN P (Drug), LUMIGAN | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: EYE CARE | ||||||
| 03/30/2023 | ABBVIE INC. | LUMIGAN (Drug), VUITY, ALPHAGAN P | Food and Beverage | In-kind items and services | $4.49 | General |
| Category: EYE CARE | ||||||
| 03/29/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Ophthalmology | ||||||
| 03/16/2023 | ABBVIE INC. | LUMIGAN (Drug), VUITY, ALPHAGAN P | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: EYE CARE | ||||||
| 02/28/2023 | ABBVIE INC. | LUMIGAN (Drug), VUITY | Food and Beverage | In-kind items and services | $35.87 | General |
| Category: EYE CARE | ||||||
| 02/21/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Ophthalmology | ||||||
| 01/19/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Ophthalmology | ||||||
| 01/12/2023 | ABBVIE INC. | ALPHAGAN P (Drug), LUMIGAN | Food and Beverage | In-kind items and services | $33.92 | General |
| Category: EYE CARE | ||||||
| 01/11/2023 | Rayner Intraocular Lenses Limited | Omidria (Drug), RayOne EMV, RayOne Spheric | Food and Beverage | Cash or cash equivalent | $13.39 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,109 | 3,594 | $4.5M | $601,577 |
| 2022 | 16 | 2,114 | 3,869 | $5.3M | $661,740 |
| 2021 | 16 | 3,141 | 4,284 | $5.2M | $632,328 |
| 2020 | 18 | 3,019 | 4,275 | $4.8M | $641,185 |
Total Patients
10,383
Total Services
16,022
Medicare Billing
$2.5M
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 546 | 1,024 | $3.8M | $363,351 | 9.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 19 | 126 | $151,200 | $86,494 | 57.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 33 | 425 | $85,000 | $23,816 | 28.0% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 505 | 714 | $128,520 | $18,294 | 14.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 143 | 143 | $42,900 | $16,456 | 38.4% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 47 | 76 | $72,200 | $16,453 | 22.8% |
| 65820 | Incision to improve eye fluid flow | Facility | 2023 | 11 | 21 | $42,000 | $12,779 | 30.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 48 | 145 | $72,500 | $11,653 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 127 | $20,955 | $11,135 | 53.1% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 131 | 131 | $32,750 | $10,218 | 31.2% |
| 15823 | Removal of excessive skin and fat of upper eyelid | Facility | 2023 | 11 | 11 | $36,000 | $6,767 | 18.8% |
| 92134 | Imaging of retina | Office | 2023 | 113 | 236 | $29,500 | $6,591 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 70 | 82 | $9,348 | $5,185 | 55.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 40 | 40 | $7,680 | $3,151 | 41.0% |
| 92133 | Imaging of optic nerve | Office | 2023 | 86 | 89 | $11,125 | $1,883 | 16.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 28 | 34 | $4,692 | $1,830 | 39.0% |
| 92002 | New patient problem focused exam of visual system | Office | 2023 | 42 | 42 | $6,552 | $1,528 | 23.3% |
| 92250 | Photography of the retina | Office | 2023 | 42 | 42 | $6,300 | $1,036 | 16.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,750 | $910.07 | 33.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,260 | $589.68 | 46.8% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 13 | 13 | $2,015 | $550.80 | 27.3% |
| 92081 | Exam of visual field with limited testing | Office | 2023 | 23 | 24 | $2,640 | $509.17 | 19.3% |
| 92285 | Photography of content of eyes | Office | 2023 | 23 | 24 | $2,880 | $397.34 | 13.8% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2022 | 664 | 1,225 | $4.5M | $438,326 | 9.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 21 | 137 | $164,400 | $98,253 | 59.8% |
About Dr. Daniel Langley, DO
Dr. Daniel Langley, DO is a Ophthalmology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659361541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Langley, DO has received a total of $3,343 in payments from pharmaceutical and medical device companies, with $317.87 received in 2024. These payments were reported across 126 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($3,144).
As a Medicare-enrolled provider, Langley has provided services to 10,383 Medicare beneficiaries, totaling 16,022 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Tulsa, OK
- Active Since 10/24/2005
- Last Updated 11/10/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659361541
Products in Payments
- LUMIGAN (Drug) $365.24
- XIIDRA (Drug) $283.46
- PROPEL (Device) $278.90
- PROKERA (Device) $237.75
- Zepto (Device) $198.15
- CEQUA (Drug) $124.34
- NGENUITY (Device) $120.48
- AcrySof IQ VIVITY IOL (Device) $109.31
- ACTHAR (Biological) $108.66
- California (Device) $105.70
- RESTASIS MULTIDOSE (Drug) $102.48
- VYZULTA (Drug) $99.06
- Cequa (Drug) $95.62
- ALPHAGAN P (Drug) $85.11
- RESTASIS (Drug) $82.43
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM (Device) $67.42
- DURYSTA (Drug) $59.78
- iStent Trabecular Micro-Bypass Stent System (Device) $55.55
- Tecnis Multifocal Family of 1-piece IOLS (Device) $55.08
- TEPEZZA (Drug) $52.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Tulsa
Dr. Thomas Finley, Md, MD
Ophthalmology — Payments: $12,116
Ophthalmology $12,116
Dr. Kelli Dyer, D.o, D.O
Ophthalmology — Payments: $6,753
Ophthalmology $6,753
Jamal Siddiqui, M.d, M.D
Ophthalmology — Payments: $6,256
Ophthalmology $6,256
Neha Sangal
Ophthalmology — Payments: $4,653
Ophthalmology $4,653
Shehzad Batliwala, D.o, D.O
Ophthalmology — Payments: $4,278
Ophthalmology $4,278
Marc Goldberg, Md, MD
Ophthalmology — Payments: $4,188
Ophthalmology $4,188